Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.70 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.66 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.64 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.64 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.59 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 0.59 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29357587 | 0.88 | ADORA3 (0.65) | ADORA3SLC29A1PRMT5WDR77DOT1L | |
| SCHEMBL20705944 | 0.88 | SLC29A1 (0.80) | ADORA3SLC29A1ADORA1ADORA2A | |
| SCHEMBL25698352 | 0.88 | SLC29A1 (0.80) | ADORA3SLC29A1ADORA1ADORA2A | |
| SCHEMBL6657467 | 0.86 | ADORA3 (0.66) | ADORA3SLC29A1ADORA1ADORA2A | |
| SCHEMBL6657460 | 0.86 | ADORA3 (0.66) | ADORA3SLC29A1ADORA1ADORA2A | |
| SCHEMBL14344858 | 0.86 | ADORA3 (0.68) | ADORA3SLC29A1PRMT5WDR77DOT1L | |
| SCHEMBL19837864 | 0.85 | ADORA3 (0.74) | ADORA3PRMT5WDR77DOT1LADORA1 | |
| SCHEMBL5675424 | 0.84 | SLC29A1 (0.80) | ADORA3SLC29A1ADORA1ADORA2A | |
| SCHEMBL10886676 | 0.84 | SLC29A1 (0.80) | ADORA3SLC29A1ADORA1ADORA2A | |
| SCHEMBL5675415 | 0.84 | SLC29A1 (0.80) | ADORA3SLC29A1ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070280946-A1 | Antibody to 5' -Deoxy-5' - Methylthioadenosine And Uses Thereof | QUARK PHARMACUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070280946-A1 | Antibody to 5' -Deoxy-5' - Methylthioadenosine And Uses Thereof | QUARK PHARMACUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070280946-A1 | Antibody to 5' -Deoxy-5' - Methylthioadenosine And Uses Thereof | MTAP, SRM, NT5C2 | ADORA3 300/4885SLC29A1 179/4885PRMT5 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.